Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
about
Protons, Photons, and the Prostate - Is There Emerging Evidence in the Ongoing Discussion on Particle Therapy for the Treatment of Prostate Cancer?Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupPoint/counterpoint. High intensity focused ultrasound may be superior to radiation therapy for the treatment of early stage prostate cancer.Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signaturesProspective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer.Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancerLong-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate CancerPredictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up studyPromise and pitfalls of heavy-particle therapy.Pre-treatment risk stratification of prostate cancer patients: A critical review.Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer.Cost implications of the rapid adoption of newer technologies for treating prostate cancerReal-time prostate motion assessment: image-guidance and the temporal dependence of intra-fraction motion.Saudi Oncology Society clinical management guidelines for prostate cancer.Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial.The impact of financial interest in intensity-modulated radiation therapy on the utilization of radiation therapy for treatment of newly diagnosed prostate cancer: a single center experienceLong-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer.The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer.Analysis of inter-fraction setup errors and organ motion by daily kilovoltage cone beam computed tomography in intensity modulated radiotherapy of prostate cancerRadiation treatment for patients with intermediate-risk prostate cancer.The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention.Comparison of hybrid volumetric modulated arc therapy (VMAT) technique and double arc VMAT technique in the treatment of prostate cancer.Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes.Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of ageThe effect of 6 and 15 MV on intensity-modulated radiation therapy prostate cancer treatment: plan evaluation, tumour control probability and normal tissue complication probability analysis, and the theoretical risk of secondary induced malignanciesTreatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plansThe clinical case for proton beam therapy.Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215Radiation dose-volume effects and the penile bulb.Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancerHigh-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients
P2860
Q26767399-52AE5A0A-C402-4D4E-9FA0-9CCFA7E70737Q27011661-7ACB81D7-A2E4-40C8-BAE0-7FC1A92C58F5Q30454149-0FC64FBE-270B-4744-8FCA-45DE08FABA51Q31133958-5B5EA2BB-EE2C-4C58-8A59-F5471FE58241Q33416583-5410AE3E-6F96-4C79-A5C8-5273652BE766Q33461489-BEA8A9FA-BFD1-4F39-A674-09DE3823D791Q33679365-19663259-01F4-4F6B-A83A-6B44250C7E00Q33679373-05113234-1494-45DD-90A4-77457B6D53C1Q33819775-55F141F9-6478-4B06-91BD-F20689CDFB34Q33924077-4B0E62D1-64DE-442F-B82E-792087B1990FQ33965083-F2025C02-E1EE-4E86-AEFA-5142923BF2D0Q34124263-5618FA1A-BC0E-4E02-98BE-A0846ABE3DF0Q34268868-1A3AC189-FFD6-4432-B3C5-53238AE062B7Q34413524-E2F7C0AE-1CAE-4276-A8F7-37AE015FC520Q34437308-D0ACC8DA-ABBD-43BA-B6DC-580F3E31D9C9Q34556112-F7B3CE22-F875-4745-A3B8-52709C50B44DQ34866179-F5A2D7BD-FA7E-4FE2-BEAB-7EA3E35807EBQ34995458-64CE5425-6C61-40A8-8BFD-6242E3756303Q34997355-AD79AFAF-1112-436F-9045-6E14FCA3ADFBQ35119267-1CF8771C-7E87-4775-8554-72B2AF013C3CQ35777339-06B14411-AEE1-47AB-AAD6-3618FEF239C9Q35898128-574FE688-8C67-46DF-87E7-CD62B7CAD456Q35936700-8776B80D-74A7-42CD-8F96-A7E8DA2C39DFQ35947920-DAED11FB-D545-46B6-AC34-E0CFCF68D84CQ35984504-99889686-4507-4205-883B-987C87003779Q35992830-CB2236F5-D8FF-4894-9E2C-A704DE6BD6CCQ36077772-BE66605D-6BF1-4D4F-86F9-A51D9BDF7D30Q36079275-7E0F2B69-6531-4C6C-9536-2B4E276DF9BCQ36156751-10BB437F-5EB6-42FC-ACD0-25F3C0D87C94Q36174829-C3D970B7-7167-42EA-BA47-F3EAAA9CADE6Q36234731-9A143EDF-3A0B-4524-85B0-93D9A1A6E8E0Q36364402-8ED7A06D-C39F-4ABD-BDCE-2B876F649F3AQ36384072-03236E91-744E-4E27-A5BE-E394E8B91AF4Q36387814-F9514513-8725-4007-9490-E0E5A712680FQ36389393-B7AB66B6-F8C0-4467-A1F9-79B2B09744A6Q36547835-F0D587EE-0207-4102-B09C-C2F136C20A10Q36569094-BC688A9A-D985-49F5-BC21-737DBEB61542Q36672809-61A79FAA-F867-443D-B958-D07A749334DAQ36680609-FAFBB764-AE75-49A9-BA40-C927B0F16D6EQ36726326-C3ABC64D-A8D1-4A02-A1FC-80F08B23EEB8
P2860
Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Long-term outcome of high dose ...... lly localized prostate cancer.
@ast
Long-term outcome of high dose ...... lly localized prostate cancer.
@en
Long-term outcome of high dose ...... lly localized prostate cancer.
@nl
type
label
Long-term outcome of high dose ...... lly localized prostate cancer.
@ast
Long-term outcome of high dose ...... lly localized prostate cancer.
@en
Long-term outcome of high dose ...... lly localized prostate cancer.
@nl
prefLabel
Long-term outcome of high dose ...... lly localized prostate cancer.
@ast
Long-term outcome of high dose ...... lly localized prostate cancer.
@en
Long-term outcome of high dose ...... lly localized prostate cancer.
@nl
P2093
P1476
Long-term outcome of high dose ...... lly localized prostate cancer.
@en
P2093
Alison M Shippy
Heather Chan
Howard Amols
Yoshiya Yamada
P304
P356
10.1016/J.JURO.2006.06.002
P407
P433
P577
2006-10-01T00:00:00Z